Diagnostic TR-FRET assays for detection of antibodies in patient samples
Cell Reports Methods · 2023
DOI: 10.1016/j.crmeth.2023.100421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports Methods, 2023. Verfasst von Hong Yue und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Serological assays are important diagnostic tools for surveying exposure to the pathogen, monitoring immune response post vaccination, and managing spread of the infectious agent among the population. Current serological laboratory assays are often limited because they require the use of specialized laboratory technology and/or work with a limited number of sample types. Here, we evaluate an alternative by developing time-resolved Förster resonance energy transfer (TR-FRET) homogeneous assays that exhibited exceptional versatility, scalability, and sensitivity and outperformed or matched currently used strategies in terms of sensitivity, specificity, and precision. We validated the performance of the assays measuring total immunoglobulin G (IgG) levels; antibodies against severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle Eastern respiratory syndrome (MERS)-CoV spike (S) protein; and SARS-CoV-2 S and nucleocapsid (N) proteins and applied it to several large sample sets and real-world applications. We further established a TR-FRET-based ACE2-S competition assay to assess the neutralization propensity of the antibodies. Overall, these TR-FRET-based serological assays can be rapidly extended to other antigens and are compatible with commonly used plate readers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
- Department of Chemistry & Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
- Center for Systems Biology, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.
- Ragon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Yue, H., Nowak, R. P., Overwijn, D., Payne, N. C., Fischinger, S., Atyeo, C., Lam, E. C., St Denis, K., Brais, L. K., Konishi, Y., Sklavenitis-Pistofidis, R., Baden, L. R., Nilles, E. J., Karlson, E. W., Yu, X. G., Li, J. Z., Woolley, A. E., Ghobrial, I. M., Meyerhardt, J. A., …, & Fischer, E. S. (2023). Diagnostic TR-FRET assays for detection of antibodies in patient samples. Cell Reports Methods. https://doi.org/10.1016/j.crmeth.2023.100421
Vancouver
Yue H, Nowak RP, Overwijn D, Payne NC, Fischinger S, Atyeo C, et al. Diagnostic TR-FRET assays for detection of antibodies in patient samples. Cell Reports Methods. 2023. doi:10.1016/j.crmeth.2023.100421
BibTeX
@article{Yue2023,
author = {Yue, Hong and Nowak, Radosław P and Overwijn, Daan and Payne, N Connor and Fischinger, Stephanie and Atyeo, Caroline and Lam, Evan C and St Denis, Kerri and Brais, Lauren K and Konishi, Yoshinobu and Sklavenitis-Pistofidis, Romanos and Baden, Lindsey R and Nilles, Eric J and Karlson, Elizabeth W and Yu, Xu G and Li, Jonathan Z and Woolley, Ann E and Ghobrial, Irene M and Meyerhardt, Jeffrey A and Balazs, Alejandro B and Alter, Galit and Mazitschek, Ralph and Fischer, Eric S},
title = {Diagnostic TR-FRET assays for detection of antibodies in patient samples},
journal = {Cell Reports Methods},
year = {2023},
doi = {10.1016/j.crmeth.2023.100421}
}
EUVIMED